We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes.
- Authors
DEFRONZO, RALPH A.; HOMPESCH, MARCUS; KASICHAYANULA, SREENEERANJ; XIAONI LIU; YING HONG; PFISTER, MARC; MORROW, LINDA A.; LESLIE, BRUCE R.; BOULTON, DAVID W.; CHING, AGATHA; LACRETA, FRANK P.; GRIFFEN, STEVEN C.
- Abstract
OBJECTIVE--To examine the effect of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on themajor components of renal glucose reabsorption (decreasedmaximum renal glucose reabsorptive capacity [TmG], increased splay, and reduced threshold), using the pancreatic/stepped hyperglycemic clamp (SHC) technique. RESEARCH DESIGN AND METHODS--Subjects with type 2 diabetes (n = 12) and matched healthy subjects (n = 12) underwent pancreatic/SHC (plasma glucose range 5.5-30.5 mmol/L) at baseline and after 7 days of dapagliflozin treatment. A pharmacodynamic model was developed to describe the major components of renal glucose reabsorption for both groups and then used to estimate these parameters from individual glucose titration curves. RESULTS- At baseline, type 2 diabetic subjects had elevated TmG, splay, and threshold compared with controls. Dapagliflozin treatment reduced the TmG and splay in both groups. However, the most significant effect of dapagliflozin was a reduction of the renal threshold for glucose excretion in type 2 diabetic and control subjects. CONCLUSIONS--The SGLT2 inhibitor dapagliflozin improves glycemic control in diabetic patients by reducing the TmG and threshold at which glucose is excreted in the urine.
- Subjects
BLOOD sugar; SODIUM-glucose cotransporters; ENZYME inhibitors; PHARMACODYNAMICS; PEOPLE with diabetes
- Publication
Diabetes Care, 2013, Vol 36, Issue 10, p3169
- ISSN
0149-5992
- Publication type
Article
- DOI
10.2337/dc13-0387